NICE reverses course, recommends Enhertu for HER2-low advanced breast cancer

17 September 2026

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Enhertu (trastuzumab deruxtecan), from Daiichi Sankyo (TYO: 4568) and AstraZeneca (LSE: AZN), for routine National Health Service (NHS) use in adults with HER2-low advanced or metastatic breast cancer whose disease has progressed after chemotherapy, making the treatment available to around 1,000 people a year in England.

This decision reverses a 2024 rejection and ends a roughly two-year standoff during which Enhertu remained the only breast cancer treatment NICE had been unable to recommend since 2018, a period in which 25 other breast cancer therapies received positive recommendations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK